Cantor Fitzgerald Reiterates “Overweight” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNSFree Report) in a report published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $28.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on MRNS. Oppenheimer reiterated a market perform rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. HC Wainwright reiterated a buy rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, March 26th. Royal Bank of Canada reiterated an outperform rating and set a $24.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, March 6th. Finally, StockNews.com cut Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $21.21.

Check Out Our Latest Research Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Stock Down 5.1 %

Shares of NASDAQ:MRNS opened at $7.52 on Wednesday. The stock’s 50-day moving average price is $9.24 and its two-hundred day moving average price is $8.59. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. Marinus Pharmaceuticals has a 12-month low of $5.57 and a 12-month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last issued its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. During the same period in the previous year, the business posted ($0.76) earnings per share. As a group, equities analysts expect that Marinus Pharmaceuticals will post -2.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Marinus Pharmaceuticals by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 2,673,231 shares of the biopharmaceutical company’s stock worth $29,058,000 after acquiring an additional 95,756 shares in the last quarter. Wellington Management Group LLP lifted its position in Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after acquiring an additional 85,455 shares in the last quarter. Barclays PLC lifted its position in Marinus Pharmaceuticals by 747.4% during the 4th quarter. Barclays PLC now owns 76,372 shares of the biopharmaceutical company’s stock worth $830,000 after acquiring an additional 67,360 shares in the last quarter. Nuveen Asset Management LLC lifted its position in Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock worth $1,519,000 after acquiring an additional 1,475 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Marinus Pharmaceuticals by 124.1% during the 4th quarter. Royal Bank of Canada now owns 15,364 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 8,507 shares in the last quarter. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Stories

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.